Search Results for: ustr

La Oficina del Representante Comercial de los Estados Unidos (USTR) ha declarado su intención de tener completadas sus propuestas sobre protección de la propiedad intelectual a comienzos de la próxima ronda de negociaciones del TPP en Vietnam, del 20 al 24 de junio de 2011. En su rápida agenda, los negociadores del TPP han anunciado que ellos esperan concluir el acuerdo para el encuentro de los miembros del Foro de Cooperación Económica Asia-Pacífico, a realizarse en Hawaii del 8 al 13 de noviembre de 2011. Continue Reading →

I have another blog that deals with U.S. employment data from the information sector. This one provides May 2010 employment and wage data from fourteen 4- and 5-digit NAICS industry groups in the “Information Sector.”

Notes on the data

Continue Reading →

The Office of the U.S. Trade Representative (USTR) has declared an intention to have all its proposals on intellectual property protections by the commencement of the next round of TPP talks in Vietnam June 20-24, 2011. On a fast timetable, TPP negotiators have already announced that they want to finalize TPP by the summit meetings of the members of the Asia-Pacific Economic Cooperation on November 8-13, 2011 in Hawaii. The TPP will impact health, access to knowledge, and without the necessary safeguards, the right to privacy.

Continue Reading →

KEI Policy Brief 2011:1
June 11, 2011, Revised August 15, 2011

Continue Reading →

Using industry assertions of R&D spending, pharmaceutical related R&D spending by the private sector was less than 8 percent of global sales in 2010.

These are the data:

2010 Global R&D by all private companies: – $67.4 billion
Source: Page 2 of the 2011 PhRMA industry profile
http://report.nih.gov/investigators_and_trainees/acd_bwf/pdf/Phrma_Industry_Profile_2011.pdf

2010 Global sales – $856 billion
Continue Reading →

NYC, 7 PM Wed, June 8, 2011.

Continue Reading →

This is a report from the FDA on 2011 new molecular entities (NMEs) approvals, through June 6, 2011. The total number of FDA approvals during that same period was 150. So far, 16 NMEs have been approved in five months, a sharp increase in approvals over the same period 2010.

6 NMEs NDAs were considered priorities
8 NDAs that were considered standard approvals
2 BLA (biologic products) that were not classified.

• NMEs were 10.7 percent of all approvals.
• The NME priority NDAs were 4 percent of FDA approvals.

Continue Reading →

On Thursday, May 26, 2011, Senator Bernie Sanders (I-VT) introduced two bills in the United States Senate that would de-link R&D costs from drug prices. The bill names and numbers are as follows:

• The Medical Innovation Prize Fund Act: S. 1137
• The Prize Fund for HIV/AIDS Act: S. 1138

Continue Reading →